FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2023483954> ?p ?o ?g. }

• W2023483954 endingPage "339" @default.
• W2023483954 startingPage "331" @default.
• W2023483954 abstract "Background Previous studies have shown that activated haplo-identical peripheral blood stem cell (haplo-PBSC) treatment exerts an anti-tumor effect on patients with metastatic solid tumors. The purpose of this study was to test the hypothesis that fetal–maternal microchimerism enhances the beneficial effect of the haplo-PBSC treatment for cancer. Methods Twenty-five patients with advanced-stage solid tumors refractory to standard chemotherapy were treated with haplo-PBSC donated by parents or children. Fetal–maternal microchimerism status was determined using nested polymerase chain reaction typing using sequence-specific primers (PCR-SSP). Clinical outcomes, including therapeutic response by measuring tumor size changes using CT scanning and survival times, were evaluated. The donor–recipient mixed lymphocyte response (MLR) was detected using an MTT proliferation assay. Cytokine production was determined using an ELISA method. Results Six patients receiving maternal–child transplants were fetal–maternal microchimerism positive (+). The mean survival time of patients with the microchimerism+ haplo-PBSC treatment was 30.17 ± 5.32 months (median 17 months), which was significantly longer than that of patients with negative (−) microchimerism (mean 16.95 ± 3.29 months, median 8 months; P = 0.043). The therapeutic response rate was significantly higher in microchimerism+ patients (83.3%) than that in microchimerism− patients (36.8%) (P = 0.047). Furthermore, suppression of donor–recipient MLR and increased production of a T-helper type 1 (Th1) type cytokine, interferon (IFN)-γ, were found in microchimerism+ patients after haplo-PBSC treatment. Discussion This small study suggests that fetal–maternal microchimerism is associated with a statistically significant improvement in anti-tumor effect of activated haplo-PBSC treatment. Further study is required to elucidate the mechanism for this observation. Previous studies have shown that activated haplo-identical peripheral blood stem cell (haplo-PBSC) treatment exerts an anti-tumor effect on patients with metastatic solid tumors. The purpose of this study was to test the hypothesis that fetal–maternal microchimerism enhances the beneficial effect of the haplo-PBSC treatment for cancer. Twenty-five patients with advanced-stage solid tumors refractory to standard chemotherapy were treated with haplo-PBSC donated by parents or children. Fetal–maternal microchimerism status was determined using nested polymerase chain reaction typing using sequence-specific primers (PCR-SSP). Clinical outcomes, including therapeutic response by measuring tumor size changes using CT scanning and survival times, were evaluated. The donor–recipient mixed lymphocyte response (MLR) was detected using an MTT proliferation assay. Cytokine production was determined using an ELISA method. Six patients receiving maternal–child transplants were fetal–maternal microchimerism positive (+). The mean survival time of patients with the microchimerism+ haplo-PBSC treatment was 30.17 ± 5.32 months (median 17 months), which was significantly longer than that of patients with negative (−) microchimerism (mean 16.95 ± 3.29 months, median 8 months; P = 0.043). The therapeutic response rate was significantly higher in microchimerism+ patients (83.3%) than that in microchimerism− patients (36.8%) (P = 0.047). Furthermore, suppression of donor–recipient MLR and increased production of a T-helper type 1 (Th1) type cytokine, interferon (IFN)-γ, were found in microchimerism+ patients after haplo-PBSC treatment. This small study suggests that fetal–maternal microchimerism is associated with a statistically significant improvement in anti-tumor effect of activated haplo-PBSC treatment. Further study is required to elucidate the mechanism for this observation." @default.
• W2023483954 created "2016-06-24" @default.
• W2023483954 creator A5003226007 @default.
• W2023483954 creator A5006042484 @default.
• W2023483954 creator A5056744141 @default.
• W2023483954 creator A5063983172 @default.
• W2023483954 creator A5068659124 @default.
• W2023483954 date "2008-01-01" @default.
• W2023483954 modified "2023-10-16" @default.
• W2023483954 title "Beneficial effects of fetal–maternal microchimerism on the activated haplo-identical peripheral blood stem cell treatment for cancer" @default.
• W2023483954 cites W132751912 @default.
• W2023483954 cites W1521169335 @default.
• W2023483954 cites W1921036032 @default.
• W2023483954 cites W1933800036 @default.
• W2023483954 cites W1965239953 @default.
• W2023483954 cites W1986354501 @default.
• W2023483954 cites W1991336323 @default.
• W2023483954 cites W2000289316 @default.
• W2023483954 cites W2007701645 @default.
• W2023483954 cites W2010634123 @default.
• W2023483954 cites W2014028676 @default.
• W2023483954 cites W2022821228 @default.
• W2023483954 cites W2060136712 @default.
• W2023483954 cites W2067666183 @default.
• W2023483954 cites W2071876985 @default.
• W2023483954 cites W2072972886 @default.
• W2023483954 cites W2088021543 @default.
• W2023483954 cites W2090682387 @default.
• W2023483954 cites W2094752997 @default.
• W2023483954 cites W2117743050 @default.
• W2023483954 cites W2118815605 @default.
• W2023483954 cites W2124740402 @default.
• W2023483954 cites W2137074910 @default.
• W2023483954 cites W2143715752 @default.
• W2023483954 cites W2152918507 @default.
• W2023483954 cites W2167805334 @default.
• W2023483954 cites W2176120669 @default.
• W2023483954 cites W2396781079 @default.
• W2023483954 cites W427860 @default.
• W2023483954 cites W77166261 @default.
• W2023483954 doi "https://doi.org/10.1080/14653240802061146" @default.
• W2023483954 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/18574766" @default.
• W2023483954 hasPublicationYear "2008" @default.
• W2023483954 type Work @default.
• W2023483954 sameAs 2023483954 @default.
• W2023483954 citedByCount "14" @default.
• W2023483954 countsByYear W20234839542013 @default.
• W2023483954 countsByYear W20234839542014 @default.
• W2023483954 countsByYear W20234839542018 @default.
• W2023483954 countsByYear W20234839542019 @default.
• W2023483954 countsByYear W20234839542022 @default.
• W2023483954 crossrefType "journal-article" @default.
• W2023483954 hasAuthorship W2023483954A5003226007 @default.
• W2023483954 hasAuthorship W2023483954A5006042484 @default.
• W2023483954 hasAuthorship W2023483954A5056744141 @default.
• W2023483954 hasAuthorship W2023483954A5063983172 @default.
• W2023483954 hasAuthorship W2023483954A5068659124 @default.
• W2023483954 hasConcept C126322002 @default.
• W2023483954 hasConcept C143998085 @default.
• W2023483954 hasConcept C162834538 @default.
• W2023483954 hasConcept C172680121 @default.
• W2023483954 hasConcept C203014093 @default.
• W2023483954 hasConcept C2776090121 @default.
• W2023483954 hasConcept C2778740727 @default.
• W2023483954 hasConcept C2779234561 @default.
• W2023483954 hasConcept C54355233 @default.
• W2023483954 hasConcept C71924100 @default.
• W2023483954 hasConcept C86803240 @default.
• W2023483954 hasConcept C8891405 @default.
• W2023483954 hasConcept C90924648 @default.
• W2023483954 hasConceptScore W2023483954C126322002 @default.
• W2023483954 hasConceptScore W2023483954C143998085 @default.
• W2023483954 hasConceptScore W2023483954C162834538 @default.
• W2023483954 hasConceptScore W2023483954C172680121 @default.
• W2023483954 hasConceptScore W2023483954C203014093 @default.
• W2023483954 hasConceptScore W2023483954C2776090121 @default.
• W2023483954 hasConceptScore W2023483954C2778740727 @default.
• W2023483954 hasConceptScore W2023483954C2779234561 @default.
• W2023483954 hasConceptScore W2023483954C54355233 @default.
• W2023483954 hasConceptScore W2023483954C71924100 @default.
• W2023483954 hasConceptScore W2023483954C86803240 @default.
• W2023483954 hasConceptScore W2023483954C8891405 @default.
• W2023483954 hasConceptScore W2023483954C90924648 @default.
• W2023483954 hasIssue "4" @default.
• W2023483954 hasLocation W20234839541 @default.
• W2023483954 hasLocation W20234839542 @default.
• W2023483954 hasOpenAccess W2023483954 @default.
• W2023483954 hasPrimaryLocation W20234839541 @default.
• W2023483954 hasRelatedWork W1964419962 @default.
• W2023483954 hasRelatedWork W1985982499 @default.
• W2023483954 hasRelatedWork W2006280372 @default.
• W2023483954 hasRelatedWork W2037133350 @default.
• W2023483954 hasRelatedWork W2087046172 @default.
• W2023483954 hasRelatedWork W2113382995 @default.
• W2023483954 hasRelatedWork W2321731952 @default.
• W2023483954 hasRelatedWork W2326168654 @default.
• W2023483954 hasRelatedWork W2793200050 @default.
• W2023483954 hasRelatedWork W4205946139 @default.

• next